Foley Hoag provides innovative, strategic legal services to public, private and government clients. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse experiences of our lawyers contribute to the exceptional senior-level service we deliver to clients.
In a conversation with Boston Business Journal after the J.P. Morgan Healthcare Conference, Jeffrey Quillen, co-chair of the firm’s Life Sciences Industry Group, discussed the state of the biotech industry heading into 2026.
United States
In a conversation with Boston Business Journal after
the J.P. Morgan Healthcare Conference, Jeffrey Quillen, co-chair of
the firm's Life Sciences Industry Group, discussed the state of
the biotech industry heading into 2026.
Quillen noted an upturn in financings and M&A activity in
the fourth quarter of 2025 and was optimistic that the momentum
would continue into 2026: "Does this have legs? Is this likely
to carry into the year? I think it does," he said. Quillen
also said that challenging conditions for the industry over
previous years weeded out weaker companies, resulting in emerging
companies of "really high quality."
Foley Hoag provides innovative, strategic legal services to public, private and government clients. We have premier capabilities in the life sciences, healthcare, technology, energy, professional services and private funds fields, and in cross-border disputes. The diverse experiences of our lawyers contribute to the exceptional senior-level service we deliver to clients.
